Accéder au contenu
Merck

Major complications, mortality, and resource utilization after open abdominal surgery: 0.9% saline compared to Plasma-Lyte.

Annals of surgery (2012-04-04)
Andrew D Shaw, Sean M Bagshaw, Stuart L Goldstein, Lynette A Scherer, Michael Duan, Carol R Schermer, John A Kellum
RÉSUMÉ

To assess the association of 0.9% saline use versus a calcium-free physiologically balanced crystalloid solution with major morbidity and clinical resource use after abdominal surgery. 0.9% saline, which results in a hyperchloremic acidosis after infusion, is frequently used to replace volume losses after major surgery. An observational study using the Premier Perspective Comparative Database was performed to evaluate adult patients undergoing major open abdominal surgery who received either 0.9% saline (30,994 patients) or a balanced crystalloid solution (926 patients) on the day of surgery. The primary outcome was major morbidity and secondary outcomes included minor complications and acidosis-related interventions. Outcomes were evaluated using multivariable logistic regression and propensity scoring models. For the entire cohort, the in-hospital mortality was 5.6% in the saline group and 2.9% in the balanced group (P < 0.001). One or more major complications occurred in 33.7% of the saline group and 23% of the balanced group (P < 0.001). In the 3:1 propensity-matched sample, treatment with balanced fluid was associated with fewer complications (odds ratio 0.79; 95% confidence interval 0.66-0.97). Postoperative infection (P = 0.006), renal failure requiring dialysis (P < 0.001), blood transfusion (P < 0.001), electrolyte disturbance (P = 0.046), acidosis investigation (P < 0.001), and intervention (P = 0.02) were all more frequent in patients receiving 0.9% saline. Among hospitals in the Premier Perspective Database, the use of a calcium-free balanced crystalloid for replacement of fluid losses on the day of major surgery was associated with less postoperative morbidity than 0.9% saline.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Acetate de sodium, anhydrous, ReagentPlus®, ≥99.0%
Sigma-Aldrich
Acétate de sodium trihydrate, ACS reagent, ≥99%
Sigma-Aldrich
Acetate de sodium, puriss. p.a., ACS reagent, reag. Ph. Eur., anhydrous
Sigma-Aldrich
Acetate de sodium, ACS reagent, ≥99.0%
Sigma-Aldrich
Acétate de sodium trihydrate, ReagentPlus®, ≥99.0%
Sigma-Aldrich
Acetate de sodium, anhydrous, for molecular biology, ≥99%
Sigma-Aldrich
Acétate de sodium trihydrate, puriss., meets analytical specification of Ph. Eur., BP, USP, FCC, E262, 99.0-101.0% (calc. to the dried substance), ≤0.00002% Al
Sigma-Aldrich
Acetate de sodium, 99.995% trace metals basis
Sigma-Aldrich
Sodium acetate solution, BioUltra, for molecular biology, ~3 M in H2O
Sigma-Aldrich
Acetate de sodium, anhydrous, BioUltra, for luminescence, for molecular biology, ≥99.0% (NT)
Sigma-Aldrich
Acetate de sodium, powder, BioReagent, suitable for electrophoresis, suitable for cell culture, suitable for insect cell culture, ≥99%
Sigma-Aldrich
Acétate de sodium trihydrate, BioUltra, ≥99.5% (NT)
Sigma-Aldrich
Acétate de sodium trihydrate, BioXtra, ≥99.0%
Sigma-Aldrich
Acétate de sodium trihydrate, meets USP testing specifications
Sigma-Aldrich
Acetate de sodium, BioXtra, ≥99.0%
Sigma-Aldrich
Acetate de sodium, meets USP testing specifications, anhydrous